JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Philippe Menasché
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azarnoush, K.
Right arrow Articles by Menasché, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azarnoush, K.
Right arrow Articles by Menasché, P.
Related Collections
Right arrow Transplantation - heart

J Thorac Cardiovasc Surg 2005;130:173-179
© 2005 The American Association for Thoracic Surgery


Cardiothoracic Transplantation

Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1{alpha}

Kasra Azarnoush, MD a , Agnès Maurel, PhD a , Laurent Sebbah, MD b , c , Claire Carrion d , Alvine Bissery, MSc e , Chantal Mandet f , Julia Pouly, MD a , g , Patrick Bruneval, MD f , h , Albert A. Hagège, MD, PhD a , b , c , Philippe Menasché, MD, PhD a , c , g , *

a INSERM, U 633, Laboratoire d’Etude des Greffes et Prothèses Cardiaques, Hôpital Broussais, Paris, France
d U 582, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
f U 430, Hôpital Broussais, Paris, France
b Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, the Department of Cardiology, Paris, France
g Department of Cardiovascular Surgery, Paris, France
h Department of Pathology, Paris, France
e Clinical Investigation Center/INSERM, Paris, France
c University of Paris 5 Rene-Descartes, Paris, France

Received for publication June 4, 2004; revisions received October 27, 2004; accepted for publication November 2, 2004.

* Address for reprints: Philippe Menasché, MD, PhD, Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France. (Email: philippe.menasche{at}hop.egp.ap-hop-paris.fr).

OBJECTIVE: Early cell death remains a major limitation of skeletal myoblast transplantation. Because the poor vascularization of the target scars contributes to cell loss, we assessed the effects of combining skeletal myoblast transplantation with administration of hypoxia-inducible factor 1{alpha}, a master gene that controls the expression of a wide array of angiogenic factors.

METHODS: A myocardial infarction was created in 56 rats by means of coronary artery ligation. Eight days later, rats were randomly allocated to receive in-scar injections of culture medium (control animals, n = 11), skeletal myoblasts (5 x 106, n = 13), adenovirus-encoded hypoxia-inducible factor 1{alpha} (1.0 x 1010 pfu/mL, n = 7), or skeletal myoblasts (5 x 106) in combination with an empty vector (n = 3) or active hypoxia-inducible factor 1{alpha} (1.0 x 1010 pfu/mL, n = 13). A fifth group (n = 9) underwent a staged approach in which hypoxia-inducible factor 1{alpha} (1.0 x 1010 pfu/mL) was injected at the time of infarction, followed 8 days later by skeletal myoblasts (5 x 106). Left ventricular function was assessed echocardiographically before transplantation and 1 month thereafter. Explanted hearts were then processed for the immunohistochemical detection of myotubes, quantification of angiogenesis, myoblast engraftment, and cell survival.

RESULTS: Baseline ejection fractions were not significantly different among groups (35%–40%). One month later, ejection fraction had decreased from baseline in control hearts and in those injected with hypoxia-inducible factor 1{alpha}. In contrast, it did not deteriorate after injections of skeletal myoblasts alone or combined with either the empty vector or active hypoxia-inducible factor 1{alpha} administered sequentially. The most striking change occurred in the skeletal myoblast plus hypoxia-inducible factor 1{alpha} combined group in which ejection fraction increased dramatically (by 27%) above baseline levels and was thus markedly higher than in all other groups (P = .0001 and P = .001 vs control animals and animals receiving hypoxia-inducible factor 1{alpha}, respectively). Compared with skeletal myoblasts alone, the coadministration of hypoxia-inducible factor 1{alpha} resulted in a significantly greater degree of angiogenesis, cell engraftment, and cell survival.

CONCLUSION: Induction of angiogenesis is an effective means of potentiating the functional benefits of myoblast transplantation, and hypoxia-inducible factor 1{alpha} can successfully achieve this goal.





This article has been cited by other articles:


Home page
Cardiovasc ResHome page
P. Menasche
Towards the second generation of skeletal myoblasts?
Cardiovasc Res, August 1, 2008; 79(3): 355 - 356.
[Full Text] [PDF]


Home page
ICVTSHome page
S. Chanseaume, K. Azarnoush, A. Maurel, V. Bellamy, S. Peyrard, P. Bruneval, A. A. Hagege, and P. Menasche
Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
Interactive CardioVascular and Thoracic Surgery, June 1, 2007; 6(3): 293 - 297.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. R. Abraham and G. Gerstenblith
Preconditioning Stem Cells for Cardiovascular Disease: An Important Step Forward
Circ. Res., March 2, 2007; 100(4): 447 - 449.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P. Menasche, M. Desnos, and A. A. Hagege
Myoblast transplantation during cardiac surgery
Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H52 - H56.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
K. H. Wu, Y. L. Liu, B. Zhou, and Z. C. Han
Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells
Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 770 - 781.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. A. Hagege, J.-P. Marolleau, J.-T. Vilquin, A. Alheritiere, S. Peyrard, D. Duboc, E. Abergel, E. Messas, E. Mousseaux, K. Schwartz, et al.
Skeletal Myoblast Transplantation in Ischemic Heart Failure: Long-Term Follow-Up of the First Phase I Cohort of Patients
Circulation, July 4, 2006; 114(1_suppl): I-108 - I-113.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Siepe, M.-N. Giraud, M. Pavlovic, C. Receputo, F. Beyersdorf, P. Menasche, T. Carrel, and H. T. Tevaearai
Myoblast-seeded biodegradable scaffolds to prevent post-myocardial infarction evolution toward heart failure
J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 124 - 131.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Fernandes, J.-C. Amirault, G. Lande, J.-M. Nguyen, V. Forest, O. Bignolais, G. Lamirault, D. Heudes, J.-L. Orsonneau, M.-F. Heymann, et al.
Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias
Cardiovasc Res, February 1, 2006; 69(2): 348 - 358.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.